Pediatrix Medical Group, Inc. (NYSE:MD) Stock Holdings Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 2.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 31,617 shares of the company’s stock after selling 770 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Pediatrix Medical Group were worth $366,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of MD. Quest Partners LLC increased its stake in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the period. SummerHaven Investment Management LLC boosted its holdings in shares of Pediatrix Medical Group by 3.8% during the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock worth $422,000 after purchasing an additional 2,069 shares during the period. Bank of Montreal Can boosted its holdings in shares of Pediatrix Medical Group by 0.5% during the second quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock worth $3,196,000 after purchasing an additional 2,083 shares during the period. Finally, Atria Investments Inc lifted its stake in Pediatrix Medical Group by 9.0% in the third quarter. Atria Investments Inc now owns 27,124 shares of the company’s stock valued at $314,000 after acquiring an additional 2,238 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $14.07 on Monday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The business has a 50-day moving average price of $13.96 and a two-hundred day moving average price of $10.78. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $16.41.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 EPS. On average, equities research analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

MD has been the subject of a number of analyst reports. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho boosted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, December 11th. UBS Group boosted their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.